Loading...
OTCM
PPCB
Market cap26mUSD
Jun 10, Last price  
8.00USD
Name

Propanc Biopharma Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
616.63%
Rev. gr., 5y
%
Revenues
0k
Net income
-2m
L-41.84%
-2,151,977-11,434,375-1,442,638-829,564-3,412,754-9,410,352-7,867,500-7,039,155-5,760,000-4,740,000-2,420,000-3,360,000-3,130,000-1,820,528
CFO
-935k
L-15.39%
-1,395,376-170,278-128,647-226,442-1,426,479-4,499,314-2,050,636-2,177,645-2,060,037-1,849,589-1,145,264-1,436,304-1,105,251-935,118

Profile

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
URL
https://www.propanc.com/
IPO date
Jun 15, 2012
Employees
1
Domiciled in
AU
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
Cost of revenue
1,536
1,834
2,019
Unusual Expense (Income)
NOPBT
(1,536)
(1,834)
(2,019)
NOPBT Margin
Operating Taxes
(129)
(130)
(55)
Tax Rate
NOPAT
(1,407)
(1,704)
(1,964)
Net income
(1,821)
-41.84%
(3,130)
-6.85%
(3,360)
38.84%
Dividends
(466)
(700)
Dividend yield
198.64%
272,241.01%
Proceeds from repurchase of equity
23
25
(667)
BB yield
-1,301,736.06%
-10.53%
259,364.43%
Debt
Debt current
890
527
1,056
Long-term debt
78
60
105
Deferred revenue
Other long-term liabilities
Net debt
947
577
1,157
Cash flow
Cash from operating activities
(935)
(1,105)
(1,436)
CAPEX
Cash from investing activities
Cash from financing activities
942
1,114
1,491
FCF
(2,365)
186
(2,427)
Balance
Cash
21
10
4
Long term investments
Excess cash
21
10
4
Stockholders' equity
(64,950)
(63,382)
(60,078)
Invested Capital
62,119
59,569
58,153
ROIC
ROCE
54.26%
48.11%
104.88%
EV
Common stock shares outstanding
1
1,739
70
Price
0.00
-99.07%
0.14
3,573.47%
0.00
-92.89%
Market cap
2
-100.00%
235
91,149.08%
257
 
EV
947
811
1,162
EBITDA
(1,514)
(1,811)
(2,014)
EV/EBITDA
Interest
666
533
569
Interest/NOPBT